Waters Corporation and LabCorp Partner to Expand HPV Testing Access
What happened
Waters Corporation and LabCorp announced a partnership on October 23, 2026, to expand access to the FDA-approved BD Onclarity HPV Assay. This collaboration will utilize LabCorp's nationwide laboratory network starting in late 2026. The initiative is designed to address persistent cervical cancer screening gaps by offering more accessible testing options to patients across the United States.
From prnewswire.com
Why it matters
The partnership aims to bridge screening gaps by making FDA-approved testing more available to underserved populations. LabCorp will integrate the HPV testing options into its clinician programs, Gaps in Care health plan programs, and Labcorp OnDemand consumer channel. This expansion supports early detection and screening efforts in the United States.
From prnewswire.com
Who's involved
- Waters CorporationGlobal life sciences and diagnostics leader partnering to expand HPV assay access.
- LabCorpGlobal leader of laboratory services providing the nationwide network for testing.
- FDARegulatory body whose approval is required for the HPV assay used in the partnership.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- LabCorpSpeculative
LabCorp could see increased revenue by expanding nationwide access to HPV testing.
Keep exploring
The entities involved
-
Waters Corporation
company
-
LabCorp
clinical laboratory company
- FDA